Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial Active — Not Recruiting Phase III NCT05852938

A Study of Zigakibart in Adults With IgA Nephropathy

A Study of Zigakibart in Adults With IgA Nephropathy — Active Not Recruiting • Phase III • NCT05852938.

📅 01 Apr 2026 ⏱ 1 min read
Active — Not Recruiting
Check the registry for current status and eligibility criteria.
Status
Active — Not Recruiting
Phase
Phase III
NCT ID
NCT05852938
Start
2023-07-06
Completion
2027-08-10
ClinicaliQ Trial Snapshot
  • A Study of Zigakibart in Adults With IgA Nephropathy — Active Not Recruiting • Phase III • NCT05852938.
  • Review the linked registry entry for study design, population, endpoints, and operational status.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Safety and Efficacy of BION-1301 in Adults with IgA Nephropathy Conditions: IgA Nephropathy, Immunoglobulin A Nephropathy Interventions: BION-1301, Placebo Lead Sponsor: Novartis Pharmaceuticals Planned Enrollment: 383 participants

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn